Try our Advanced Search for more refined results

Daiichi Sankyo, Inc. et al v. United States Patent and Trademark Office et al

  1. July 12, 2023

    Court Tosses AstraZeneca's Challenge To USPTO's Fintiv Rule

    A Virginia federal judge threw out a suit from pharmaceutical giant AstraZeneca that challenged a rule providing guidelines on whether the Patent Trial and Appeal Board should deny patent reviews due to looming district court trials.

  2. April 06, 2023

    USPTO Says Revival Of Fintiv Suit Doesn't Help AstraZeneca

    The U.S. Patent and Trademark Office has argued that a recent court decision reviving Apple's lawsuit against the office does not support a separate challenge to a rule providing guidelines on whether the Patent Trial and Appeal Board should deny patent reviews due to looming district court trials.

  3. July 25, 2022

    AstraZeneca Says Vidal Memo Backs Case Against Fintiv Rule

    AstraZeneca lawyers want a Virginia federal judge to give her take on a memo recently penned by U.S. Patent and Trademark Office Director Kathi Vidal that adjusted how patent board judges decide whether to take on petitions that are attached to patent cases with upcoming trial dates.

  4. April 08, 2022

    PTAB To Review Cancer Antibody IP That Drew $41.8M Verdict

    The Patent Trial and Appeal Board has agreed to review a Seagen Inc. antibody patent after the board previously used its discretion to reject two challenges from Daiichi Sankyo Inc. and AstraZeneca while a Texas federal jury on Friday found Daiichi willfully infringed the patent to the tune of $41.8 million.

  5. February 23, 2022

    AstraZeneca Says Patent Office's Fintiv Rule Unlike Any Other

    Pharmaceutical giant AstraZeneca says that the way the U.S. Patent and Trademark Office made the so-called Fintiv rule precedential differs so much from the procedure at other federal agencies that the rule can't be allowed to stand.

  6. August 06, 2021

    AstraZeneca Asks Judge To Bar Use Of Fintiv Rule In PGRs

    Pharmaceutical giant AstraZeneca is the latest to say the Patent Trial and Appeal Board's policy of rejecting patent reviews based on district court litigation violates the law, arguing in a new lawsuit that applying the policy to post grant reviews renders those procedures "meaningless."